We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Crown Bioscience Strengthens Immuno-Oncology Capabilities
News

Crown Bioscience Strengthens Immuno-Oncology Capabilities

Crown Bioscience Strengthens Immuno-Oncology Capabilities
News

Crown Bioscience Strengthens Immuno-Oncology Capabilities

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Crown Bioscience Strengthens Immuno-Oncology Capabilities"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Crown Bioscience has announced that it has developed and validated a unique set of models for immuno-oncology called HuGEMM™. “Up until now, the lack of models available to test the in vivo efficacy of new antibody-based immunotherapies and combination therapies has hindered the research process,” said Jean-Pierre Wery, Ph.D., president of Crown Bioscience.

“With HuGEMM™, there is now a robust model system in place to enable scientists to assess the efficacy of human biologic therapeutics directly without resorting to mouse surrogates.” Syngeneic mouse tumor models, commonly used for testing surrogate anti-mouse PD-1 antibodies, cannot serve as models for human-specific therapeutics.

CrownBio’s HuGEMM™, which was developed by directly replacing the murine PD-1 protein with its human counterpart, can be used to evaluate human therapeutics for checkpoint inhibitors including but not limited to anti-human PD-1, anti-human PD-L1 and anti-human CTLA-4 antibodies.

With the inclusion of the HuGEMM™ models, CrownBio solidifies its role as a leader in the preclinical immuno-oncology space. HuGEMM™ joins a portfolio of well-established translational model platforms, including the collection of HuPrime® cancer models available through the company’s HuBase® annotated database.

The HuGEMM™ models were developed in collaboration with CrownBio’s partner, Nanjing Galaxy Biopharmaceutical Co., Ltd. The partnership of CrownBio and Nanjing Galaxy is expected to continue to advance both organizations’ research capabilities in immuno-oncology.

Advertisement